Opinions Plus
Perspectives on issues affecting biopharma and health care.
Most Read
Public distrust is high, PBMs are the problem, but the future is bright: a survey of biopharma pros
Doctors, beware: Prosecutors are zooming in on health care fraud as opioid crisis mounts
From the C-Suite: nurturing diversity in the workplace
Tell us what you really think: A survey on drug prices, biotech, and Alex Azar
From the C-Suite: Biotech execs share their best interview questions — and the answers they want to hear
Rare diseases are losing their immunity in formulary exclusion lists
Why medtech is a different beast than biotech in the life sciences pack
All Coverage
advertisement
